NMNH(β-Nicotinamide mononucleotide Reduced )
9 Inquiries
108347-85-9
Food/Industrial Grade
99%
SHENZHEN
Maintain
10 g/bag
Yes
2027-10-30
NMN,NAD,NR,NADPH,NADP,NADH
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceNMNH (reduced Nicotinamide Mononucleotide) is a new potent NAD+ precursor. It is a new form of NMN, can increase NAD levels to a much higher extent.NMNH is a fluorescent molecule, in contrast to NMN. The molecular formulae for NMNH is C11H17N2O8P and it is also known as 1-(5-O-phosphono-beta-D-ribofuranosyl) -1,4-dihydropyridine-3-carboxamide Reduced nicotinamide mononucleotide.
β-Nicotinamide mononucleotide, reduced form disodium (β-NMN) is the oxidized form of NAD+ precursor and is a NAD+ enhancer. β-Nicotinamide mononucleotide, reduced form disodium can be reduced to dihydronicotinamide mononucleotide (NMNH). NMNH inhibits glycolysis, TCA cycle, and cell growth.Basic Info-
Product Name:
β-nicotinamide mononucleotide, reduced form, disodium salt(NMNH)
Other Name:β-nicotinamide mononucleotide, reduced form, disodium salt(NMNH);NMNH β-nicotinamide mononucleotide, reduced form, disodium salt;NMNH;β-nicotinamide mononucleotide, reduced form, disodium salt;β-Nicotinamide mononucleotide, reduced form;NMNH(β-Nicotinamide mononucleotide Reduced );β-nicoChemicalbooktinamidemononucleotide,reducedform,disodiumsalt;β-Nicotinamide mononucleotide Reduced
CAS No.:108347-85-9
Molecular Formula:C11H18N2NaO8P
InChIKeys:LSKSZICSFLRXJW-RAJFINMANA-N
Molecular Weight:360.23
Color/Form:Light yellow to yellow
Categories:
-
-
Seller Information
-
Business Type:
Distributor
-
Main Products:
NMN,NAD,NR,NADPH,NADP,NADH
-
Location:
Floor 4,G17,Lianhui Building,No.5 Xinggong village,Sanlian Community,onghua District,Shenzhen,China.
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,100% TT in advance
-
Average lead Time:
305 days
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2021
Company Certificates-
HALAL
-
FDA
-
ISO9001
">Maintain is focusing on the leading coenzyme industry and produce high value-added coenzymes.Biocatalysis is our main technology . Enzymatic synthesis geting less impurities, highest yield, and 0 chemical solvents,enzymatic synthesis is Green enzyme technology ,no toxic,Aqueous reaction system ,100% water condition. Also bulk storage and fast delivery.
Our main products NAD,NADH NMN and NR are widely used in Dietary Supplements, cosmetic products & Pharmaceutical products.
-
-
Inquiry History9 Inquiries
Country Product Purchase Quantity Date Posted
India
NMNH(β-Nicotinamide mononucleotide Reduced )
20 KG Oct 31, 2023
United States
NMNH(β-Nicotinamide mononucleotide Reduced )
35 KG Aug 27, 2025
Philippines
a-nmn
1 KG Feb 23, 2026
United States
NMNH
50 G Jun 11, 2024
Switzerland
NMNH
50 G Mar 26, 2024
Philippines
Nmnh
100 G Dec 13, 2023
Ireland
NMNH
1 KG Dec 25, 2023
United States
NMNH
500 G Dec 13, 2023
United States
NMNH(β-Nicotinamide mononucleotide Reduced )
500 G Nov 15, 2023 Post an enquiry for this product
More from this Seller
-
-
-
Fisetin 98%
$705.6-882/KG FOB
-
-
-
-
L-5-Methyltetrahydrofolate Calcium 99% white powder MT Maintain
Food Grade / 99%
$1857.49/KG FOB
-
-
-
-
Thymulin
Reagent Grade / 99%
-
-
-
-
Trigonelline N-methylnicotinate 535-83-1
Food Grade / 98%
-
-
-
-
a -MSH (11-13) (free acid)KPV
Reagent Grade / 99%
-
-
-
-
Spermidine 99% white powder MT Maintain
Food Grade / 99%
$2000.38/KG FOB
-
NMNH increases NAD levels to a much higher extent and faster than NMN or NR, and that it is metabolized through a different, NRK and NAMPT‐independent, pathway. We also demonstrate that NMNH reduces damage and accelerates repair in renal tubular epithelial cells upon hypoxia/reoxygenation injury. Finally, we find that NMNH administration in mice causes a rapid and sustained NAD surge in whole blood, which is accompanied by increased NAD levels in liver, kidney, muscle, brain, brown adipose tissue, and heart, but not in white adipose tissue. Together, our data highlight NMNH as a new NAD precursor with therapeutic potential for acute kidney injury, confirm the existence of a novel pathway for the recycling of reduced NAD precursors and establish NMNH as a member of the new family of reduced NAD precursors.

